Praxis Precision Medicines (PRAX) Revenue (2023 - 2024)
Praxis Precision Medicines (PRAX) posted quarterly Revenue of $7.5 million for Q4 2024, up 1349.13% year-over-year from $515000.0 in Q1 2024, and up 2371.19% quarter-over-quarter from $302000.0 in Q3 2024.
Praxis Precision Medicines (PRAX) Revenue (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' Revenue history runs 2 years deep, the most recent figure standing at $7.5 million for Q4 2024.
- In Q4 2024, Revenue rose 1349.13% year-over-year to $7.5 million; the TTM figure through Sep 2025 stood at $7.5 million (up 364.98% YoY), while the FY2024 annual figure was $8.6 million, up 249.53% from the prior year.
- Revenue for Q4 2024 stood at $7.5 million, up from $302000.0 in the prior quarter.
- The five-year high for Revenue was $7.5 million in Q4 2024, with the low at $302000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Praxis Precision Medicines | 10.24 Bn | 9.48 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 302,000.00 |
| Jun 30, 2024 | 357,000.00 |
| Mar 31, 2024 | 431,000.00 |
| Dec 31, 2023 | 515,000.00 |
| Sep 30, 2023 | 468,000.00 |
| Jun 30, 2023 | 781,000.00 |
| Mar 31, 2023 | 683,000.00 |